230 related articles for article (PubMed ID: 22547623)
21. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Ibrahim M; Truffot-Pernot C; Andries K; Jarlier V; Veziris N
Am J Respir Crit Care Med; 2009 Sep; 180(6):553-7. PubMed ID: 19590024
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
Lenaerts AM; Chase SE; Chmielewski AJ; Cynamon MH
Antimicrob Agents Chemother; 1999 Oct; 43(10):2356-60. PubMed ID: 10508006
[TBL] [Abstract][Full Text] [Related]
23. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
24. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.
Ahmad Z; Fraig MM; Bisson GP; Nuermberger EL; Grosset JH; Karakousis PC
Antimicrob Agents Chemother; 2011 Apr; 55(4):1527-32. PubMed ID: 21282447
[TBL] [Abstract][Full Text] [Related]
25. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
26. Isoniazid and Rifapentine Treatment Eradicates Persistent
Foreman TW; Bucşan AN; Mehra S; Peloquin C; Doyle LA; Russell-Lodrigue K; Gandhi NR; Altman J; Day CL; Ernst JD; Blumberg HM; Rengarajan J; Kaushal D
Am J Respir Crit Care Med; 2020 Feb; 201(4):469-477. PubMed ID: 31647877
[No Abstract] [Full Text] [Related]
27. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
Dhillon J; Dickinson JM; Sole K; Mitchison DA
Antimicrob Agents Chemother; 1996 Mar; 40(3):552-5. PubMed ID: 8851569
[TBL] [Abstract][Full Text] [Related]
28. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
29. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
[TBL] [Abstract][Full Text] [Related]
30. Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Liu Y; Pertinez H; Ortega-Muro F; Alameda-Martin L; Harrison T; Davies G; Coates A; Hu Y
J Antimicrob Chemother; 2018 Mar; 73(3):724-731. PubMed ID: 29244108
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.
Rifat D; Prideaux B; Savic RM; Urbanowski ME; Parsons TL; Luna B; Marzinke MA; Ordonez AA; DeMarco VP; Jain SK; Dartois V; Bishai WR; Dooley KE
Sci Transl Med; 2018 Apr; 10(435):. PubMed ID: 29618565
[TBL] [Abstract][Full Text] [Related]
32. Metformin Adjunctive Therapy Does Not Improve the Sterilizing Activity of the First-Line Antitubercular Regimen in Mice.
Dutta NK; Pinn ML; Karakousis PC
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559262
[TBL] [Abstract][Full Text] [Related]
33. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Lenaerts AJ; Hoff D; Aly S; Ehlers S; Andries K; Cantarero L; Orme IM; Basaraba RJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3338-45. PubMed ID: 17517834
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
[No Abstract] [Full Text] [Related]
35. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Lenaerts AM; Chase SE; Cynamon MH
Antimicrob Agents Chemother; 2000 Nov; 44(11):3167-8. PubMed ID: 11036043
[TBL] [Abstract][Full Text] [Related]
37. Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
Holland DP; Hamilton CD; Stout JE
Int J Tuberc Lung Dis; 2016 Jun; 20(6):827-31. PubMed ID: 27155188
[TBL] [Abstract][Full Text] [Related]
38. Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
Dutta NK; Pinn ML; Karakousis PC
Antimicrob Agents Chemother; 2014 Sep; 58(9):5567-9. PubMed ID: 24936590
[TBL] [Abstract][Full Text] [Related]
39. Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Miyazaki E; Chaisson RE; Bishai WR
Antimicrob Agents Chemother; 1999 Sep; 43(9):2126-30. PubMed ID: 10471552
[TBL] [Abstract][Full Text] [Related]
40. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
